Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163397
Status:
COMPLETED
Last Update Posted:
2016-11-30
First Post:
2005-09-12
Brief Title:
Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma 18 to 75 y BY9010M1-137
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Comparative Study of Inhaled Ciclesonide 160 mcgDay vs Budesonide 400 mcgDay in Patients With Asthma
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to investigate the efficacy of ciclesonide versus budesonide on lung function symptoms and use of rescue medication in patients with asthma Ciclesonide and budesonide will be inhaled once daily at one dose level each The study duration consists of a baseline period 1 to 4 weeks and a treatment period 12 weeks The study will provide further data on safety and tolerability of ciclesonide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None